Genova Diagnostics – Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) offers unique insight into overall and gastrointestinal health by assessing a combination of novel stool biomarkers.

This stool analysis evaluates:

•  Digestion/Absorption Markers
•  Immunology (Inflammation) Markers
• Pancreatic Enzymes, assessment of pancreatic function Immunology (Inflammation) Markers
• Calprotectin, an FDA-cleared biomarker that effectively differentiates between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD)
• Gut Metabolic Markers
• Gut Microbiology Markers
• Gold standard O&P (ova & parasite) technology as well as EIA (Enzyme Immunoassay) for identification of common parasites

The Bacterial Overgrowth of the Small Intestine Breath Test (SIBO/BOSI) is appropriate for patients who demonstrate:

Irritable Bowel Syndrome (IBS), the most commonly diagnosed gastrointestinal disorder, affecting 20% of the general population. The SIBO test aids in identifying the actual cause of IBS.  Studies suggest that as many as 50-75% of patients with IBS have SIBO/BOSI, as demonstrated by hydrogen breath testing.

Unexplained abdominal symptoms, especially gas and bloating.

The inability to tolerate sweet or starchy foods, fiber, or friendly flora supplements.